The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study.
Viktor Grünwald
No relevant relationships to disclose
Steffen Weikert
No relevant relationships to disclose
Ingo G. H. Schmidt-Wolf
No relevant relationships to disclose
Stefan Hauser
No relevant relationships to disclose
Ahmed Magheli
No relevant relationships to disclose
Matthias Schroff
Employment or Leadership Position - MOLOGEN
Stock Ownership - MOLOGEN
Manuel Schmidt
Employment or Leadership Position - MOLOGEN
Burghardt Wittig
Consultant or Advisory Role - MOLOGEN
Stock Ownership - MOLOGEN